Tag Archive for: IND-enabling studies

Rewind Therapeutics Secures Additional Financing to Advance Oral GPR17 Remyelination Program

Financing will be used to advance Rewind’s lead oral program designed to promote remyelination and restore neurological function Peer-reviewed data published in PLOS ONE demonstrated remyelination and functional recovery following oral treatment with a selective GPR17 antagonist in preclinical models Leuven, Belgium – 6 October 2026 – Rewind Therapeutics (“Rewind”), a biotechnology company developing small-molecule […]

FundaMental Pharma appoints depression drug developer Dr. Hans Eriksson as Chief Medical Officer to advance its lead treatment-resistant depression candidate

Exceptional track record across multiple clinical development programs for depression, three of which have resulted in regulatory approvals Appointment strengthens confidence in clinical readiness and execution as the Company progresses toward first-in-human development Heidelberg, Germany – 2 June 2026 – FundaMental Pharma GmbH (or “the Company”), a preclinical-stage biopharmaceutical company focused on developing innovative, dual-acting N-methyl-D-aspartate […]

© Optimum Strategic Communications.